Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Cell Death & Disease
Das, Ishani I; Wilhelm, Margareta M; Höiom, Veronica V; Franco Marquez, Rodolfo R; Costa Svedman, Fernanda F; Hansson, Johan J; Tuominen, Rainer R; Egyhàzi Brage, Suzanne S
Genomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy.
Oncology Letters
Englert-Golon, Monika M; Burchardt, Bartosz B; Budny, Bartlomiej B; Dębicki, Szymon S; Majchrzycka, Blanka B; Wrotkowska, Elzbieta E; Jasiński, Piotr P; Ziemnicka, Katarzyna K; Słopień, Radosław R; Ruchała, Marek M; Sajdak, Stefan S
Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer.
Oncotarget
Karlsson, Anna A; Brunnström, Hans H; Lindquist, Kajsa Ericson KE; Jirström, Karin K; Jönsson, Mats M; Rosengren, Frida F; Reuterswärd, Christel C; Cirenajwis, Helena H; Borg, Åke Å; Jönsson, Per P; Planck, Maria M; Jönsson, Göran G; Staaf, Johan J
Bleeker, Fonnet E FE; Lamba, Simona S; Zanon, Carlo C; Molenaar, Remco J RJ; Hulsebos, Theo J M TJ; Troost, Dirk D; van Tilborg, Angela A AA; Vandertop, W Peter WP; Leenstra, Sieger S; van Noorden, Cornelis J F CJ; Bardelli, Alberto A